Known targets — ChEMBL curated mechanism
DRD2DRD3HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7
The experimentally established mechanism targets of Amisulpride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 9/20 | 0.98 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 0.98 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.98 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.98 |
| ▸ | TSHR | P16473 | 3/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.98 |
| ▸ | HRH1 | P35367 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 2/20 | 0.65 |
| ▸ | DRD1 | P21728 | 2/20 | 0.65 |
| ▸ | DRD4 | P21917 | 2/20 | 0.65 |
| ▸ | CA9 | Q16790 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amisulpride SCHEMBL20660127 | 1.00 | DRD2 (0.98) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL21046204 | 1.00 | DRD2 (0.98) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL29508640 | 0.99 | DRD2 (1.00) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL29506665 | 0.99 | DRD2 (1.00) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL20206474 | 0.99 | DRD2 (1.00) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL29508664 | 0.99 | DRD2 (1.00) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL675545 | 0.99 | DRD2 (1.00) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL6403721 | 0.99 | DRD2 (1.00) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL34126 | 0.99 | DRD2 (1.00) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL29083722 | 0.97 | DRD2 (0.96) | DRD2DRD3TSHRADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3720435-B1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230404924-A1 | MODIFIED RELEASE FORMULATIONS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. | 2023-12-21 | — | — | US | disclosed |
| US-11767293-B2 | Crystal forms and production methods thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230285356-A1 | NONRACEMIC MIXTURES AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. | 2023-09-14 | — | — | US | disclosed |
| US-11654113-B2 | Modified release formulations and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230072389-A1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2023-03-09 | — | — | US | disclosed |
| US-11517558-B2 | Nonracemic mixtures and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-06 | — | — | US | disclosed |
| US-11370753-B2 | Crystal forms and production methods thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220117899-A1 | MODIFIED RELEASE FORMULATIONS AND USES THEREOF | SUMITOMO DAINIPPON PHARMA COMPANY, LIMITED (JP) | 2022-04-21 | — | — | US | disclosed |
| US-11160758-B2 | Modified release formulations and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-10660875-B1 | Nonracemic mixtures and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20200147040-A1 | NONRACEMIC MIXTURES AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-05-14 | — | — | US | disclosed |
| US-10576058-B2 | Nonracemic mixtures and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577317-B2 | Crystal forms and production methods thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190315686-A1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190314331-A1 | NONRACEMIC MIXTURES AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-10-17 | — | — | US | disclosed |
| US-10377708-B2 | Crystal forms and production methods thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10369134-B2 | Nonracemic mixtures and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20190167635-A1 | NONRACEMIC MIXTURES AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190169123-A1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11654113-B2 | Modified release formulations and uses thereof | SRI, ABCG2, SUCNR1 | DRD2 1099/4885DRD3 1089/4885HTR2B 404/4885 |
| US-10369134-B2 | Nonracemic mixtures and uses thereof | TPMT, AASDHPPT, SIGMAR1 | DRD2 1465/4885DRD3 1446/4885HTR2B 564/4885 |
| US-11160758-B2 | Modified release formulations and uses thereof | SRI, ABCG2, SUCNR1 | DRD2 1099/4885DRD3 1089/4885HTR2B 404/4885 |
| US-11767293-B2 | Crystal forms and production methods thereof | CYP4F3, HMGCR, LSS | DRD2 752/4885DRD3 443/4885HTR2B 122/4885 |
| US-20190314331-A1 | NONRACEMIC MIXTURES AND USES THEREOF | TPMT, AASDHPPT, SIGMAR1 | DRD2 1465/4885DRD3 1446/4885HTR2B 564/4885 |
| US-20230072389-A1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | CYP4F3, HMGCR, LSS | DRD2 752/4885DRD3 443/4885HTR2B 122/4885 |
| US-20190167635-A1 | NONRACEMIC MIXTURES AND USES THEREOF | TPMT, AASDHPPT, SIGMAR1 | DRD2 1465/4885DRD3 1446/4885HTR2B 564/4885 |
| US-20230285356-A1 | NONRACEMIC MIXTURES AND USES THEREOF | TPMT, AASDHPPT, SIGMAR1 | DRD2 1465/4885DRD3 1446/4885HTR2B 564/4885 |
| US-11517558-B2 | Nonracemic mixtures and uses thereof | TPMT, AASDHPPT, SIGMAR1 | DRD2 1465/4885DRD3 1446/4885HTR2B 564/4885 |
| US-20190169123-A1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | CYP4F3, HMGCR, LSS | DRD2 752/4885DRD3 443/4885HTR2B 122/4885 |
| US-20190315686-A1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | CYP4F3, HMGCR, LSS | DRD2 752/4885DRD3 443/4885HTR2B 122/4885 |
| US-20220117899-A1 | MODIFIED RELEASE FORMULATIONS AND USES THEREOF | SRI, ABCG2, SUCNR1 | DRD2 1099/4885DRD3 1089/4885HTR2B 404/4885 |
| US-20230404924-A1 | MODIFIED RELEASE FORMULATIONS AND USES THEREOF | SRI, ABCG2, SUCNR1 | DRD2 1099/4885DRD3 1089/4885HTR2B 404/4885 |
| US-20200147040-A1 | NONRACEMIC MIXTURES AND USES THEREOF | TPMT, AASDHPPT, SIGMAR1 | DRD2 1465/4885DRD3 1446/4885HTR2B 564/4885 |
| US-10577317-B2 | Crystal forms and production methods thereof | CYP4F3, HMGCR, LSS | DRD2 752/4885DRD3 443/4885HTR2B 122/4885 |
| US-10660875-B1 | Nonracemic mixtures and uses thereof | TPMT, AASDHPPT, SIGMAR1 | DRD2 1465/4885DRD3 1446/4885HTR2B 564/4885 |
| US-10576058-B2 | Nonracemic mixtures and uses thereof | TPMT, AASDHPPT, SIGMAR1 | DRD2 1465/4885DRD3 1446/4885HTR2B 564/4885 |
| US-11370753-B2 | Crystal forms and production methods thereof | CYP4F3, HMGCR, LSS | DRD2 752/4885DRD3 443/4885HTR2B 122/4885 |
| US-10377708-B2 | Crystal forms and production methods thereof | CYP4F3, HMGCR, LSS | DRD2 752/4885DRD3 443/4885HTR2B 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.